Please login to the form below

Not currently logged in
Email:
Password:

PureTech Health appoints new chief financial officer

Joep Muijrers joins the biopharma from Life Sciences Partners

Joep MuijrersClinical-stage biopharmaceutical company PureTech Health has bolstered the team with a new chief financial officer in the form of Joep Muijrers.

Muijrers most recently served as a partner and portfolio manager at Life Sciences Partners, a trans-Atlantic investor group with an exclusive focus on the life science industry.

During his 11 years at the company, Muijrers’ responsibilities saw him help several companies strengthen its biopharmaceutical status.

Daphne Zohar, founder and chief executive officer of PureTech Health, said: “We are delighted to have Joep join PureTech Health and bring his diverse experience in life sciences and impressive track record of significant value creation to our team as we enter this next important phase of our growth.”

Muijrers has worked with pharmaceutical clients such as Kite Pharma, Ablynx and Juno Therapeutics, and said: “I am thrilled to join PureTech Health, one of the most exiciting and unique biopharma companies I have come across in my career.”

In his new role, Muijrers will be take the helm of all aspects of the company’s finances, including capital markets strategy and execution, driving monetisation events for growth stage affiliates, strategic and financial planning and financial reporting.

25th April 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

David Atkins
A snapshot of Congenica
PME talks to CEO David Atkins...
Data desires
What are you looking to achieve with data and how are you preparing yourself to react to the results?...
The balancing act that’s keeping pharma and biotech market access on its toes
Pricing drugs and gaining reimbursement can be a real challenge for drug developers. Price it too high, and no one buys it. Price it too low, and it’s hard to...

Infographics